Chemotherapy Induced Nausea Vomiting Market Report and Forecast 2025-2034
Description
The chemotherapy induced nausea vomiting market was valued at USD 1.72 Billion in 2024 driven by innovations in treatment options across the 8 major markets. It is expected to grow at a CAGR of 4.50% during the forecast period of 2025-2034 and attain a market value of USD 2.67 Billion by 2034. The rising cancer incidence is boosting the need for effective antiemetics, supporting long-term market expansion. Advancements in R&D and personalized medicine are driving innovation in targeted and combination chemotherapy induced nausea and vomiting treatments.
Chemotherapy Induced Nausea Vomiting Market Overview
Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of cancer treatment, caused by the body’s reaction to chemotherapy drugs. It can occur during or after treatment and may be acute, delayed, or anticipatory. CINV significantly affects patients' quality of life and treatment adherence, making the use of antiemetic medications essential for effective symptom management and patient comfort. The market is expected to grow at a CAGR of 4.50% during the forecast period of 2025-2034.
Chemotherapy Induced Nausea Vomiting Market Growth Drivers
Adoption of Ready-to-use Injectables to Drive Market Growth
Growing demand for convenient, safe, and efficient antiemetic delivery, along with a rising focus on pediatric and high-risk cancer patients, is shaping the evolution of the market. For instance, in July 2024, Amneal Pharmaceuticals and Steriscience launched a novel ready-to-use injectable formulation of fosaprepitant, free from Polysorbate 80 and requiring no reconstitution. This single-dose vial, FOCINVEZ, supports adult and pediatric CINV prevention in highly and moderately emetogenic chemotherapy. The innovation enhances hospital and clinic workflow efficiency while improving patient safety and adherence. This launch is expected to significantly contribute to market growth during the forecast period by offering differentiated, patient-centric antiemetic solutions that align with ongoing demand for ready-to-administer therapies.
Chemotherapy Induced Nausea Vomiting Market Trends
Major market trends include rising clinical innovations, preference for combination therapies, and an emphasis on providing solutions for children among others.
Clinical Innovations to Bring Advanced Solutions in the Market
In October 2024, a phase 3 clinical study presented at the ASCO Quality Care Symposium revealed that olanzapine significantly outperformed prochlorperazine in managing severe refractory nausea after chemotherapy. This highlights a shift toward patient-centric treatment strategies beyond standard antiemetics. As clinical validation supports olanzapine’s efficacy, its wider adoption is expected to reshape supportive oncology care and drive growth in the CINV market during the forecast period.
Strategic Licensing to Fuel Combination Therapies and Impact Market Size Positively
In January 2023, Glenmark Pharmaceuticals launched Akynzeo IV, an injectable fixed-dose combination of fosnetupitant and palonosetron, under an exclusive licensing deal with Helsinn. This ready-to-dilute formulation simplifies administration in clinical settings, especially for highly emetogenic chemotherapy. Strategic partnerships like this are strengthening access to next-generation combination therapies, accelerating product adoption, and boosting the market’s growth.
Rising Pediatric Focus to Advance Targeted Chemotherapy Induced Nausea Vomiting Treatment
The growing inclusion of pediatric patients in chemotherapy regimens is increasing demand for age-specific antiemetic treatments. Formulations approved for use in young children are gaining traction as healthcare providers prioritize early intervention. This demographic shift is prompting pharmaceutical companies to invest in research and regulatory approvals for pediatric-friendly CINV therapies, opening new avenues for market expansion in the coming years.
Increased Hospital Reliance on Ready-to-use Injectables Supporting Chemotherapy Induced Nausea Vomiting Market Growth
With healthcare systems seeking efficiency and safety in drug administration, the demand for ready-to-use injectables is rising. These formulations reduce preparation time, minimize contamination risks, and improve workflow in oncology settings. As more antiemetic drugs are developed in pre-filled or single-dose formats, hospitals and cancer centres are expected to prefer them over traditional injectable therapies, thereby supporting growth in the market.
Chemotherapy Induced Nausea Vomiting Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Serotonin Receptor Antagonists to Lead the Market Share by Therapy
Serotonin receptor antagonists are expected to hold a substantial share due to their widespread use and proven efficacy. NK-1 receptor antagonists follow, offering enhanced control in combination therapies. The others category, including corticosteroids and novel agents, holds a smaller share but contributes to comprehensive treatment approaches, especially in patients with refractory symptoms or complex chemotherapy regimens.
Chemotherapy Induced Nausea Vomiting Market Analysis by Region
The United States is likely to hold the largest market share, driven by high chemotherapy adoption rates and access to advanced antiemetic therapies. Japan follows closely due to its ageing population and strong oncology care infrastructure. European countries Germany, France, Italy, Spain, and the UK, exhibit moderate growth with standardized treatment guidelines. India shows emerging potential, though limited access and affordability constraints currently restrict its overall market contribution.
Leading Players in the Chemotherapy Induced Nausea Vomiting Market
The key features of the market report comprise epidemiology, clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Dr. Reddy’s Laboratories Ltd.
Founded in 1984 and headquartered in Hyderabad, India, Dr. Reddy’s Laboratories is a global pharmaceutical company with a strong presence in generics, active pharmaceutical ingredients, and biosimilars. In the chemotherapy-induced nausea and vomiting (CINV) market, it offers antiemetic formulations like Ondansetron and Palonosetron, supporting cancer care through affordable, high-quality medicines distributed across regulated and emerging markets.
CTX Lifesciences
Established in 2004 and headquartered in Surat, India, CTX Lifesciences is known for manufacturing APIs and intermediates, particularly for oncology and antiemetic segments. In the CINV market, the company provides active pharmaceutical ingredients like Ondansetron and Granisetron to global formulation companies, supporting cost-effective antiemetic drug production across various international regulatory frameworks.
Pfizer Inc.
Headquartered in New York, USA, and founded in 1849, Pfizer is one of the world's largest biopharmaceutical companies. In the chemotherapy-induced nausea and vomiting (CINV) segment, Pfizer markets leading antiemetic products like Emend (Aprepitant), an NK1 receptor antagonist. Its innovative oncology support therapies are widely used in hospitals and oncology clinics globally.
Glenmark Pharmaceuticals Inc.
Founded in 1977 and headquartered in Mumbai, India, Glenmark Pharmaceuticals operates internationally with a strong generics and specialty drug portfolio. In the chemotherapy induced nausea vomiting market, it offers generic formulations such as Ondansetron and Palonosetron. Glenmark supports global cancer treatment protocols by delivering accessible and effective antiemetic drugs to healthcare systems across developed and developing regions.
Other key players in the market include Gmt Pharma, Mountainside Medical, Cipla Limited, GlaxoSmithKline plc, Merck and Co. Inc., and Novartis AG.
Key Questions Answered in the Chemotherapy Induced Nausea Vomiting Market
Chemotherapy Induced Nausea Vomiting Market Overview
Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of cancer treatment, caused by the body’s reaction to chemotherapy drugs. It can occur during or after treatment and may be acute, delayed, or anticipatory. CINV significantly affects patients' quality of life and treatment adherence, making the use of antiemetic medications essential for effective symptom management and patient comfort. The market is expected to grow at a CAGR of 4.50% during the forecast period of 2025-2034.
Chemotherapy Induced Nausea Vomiting Market Growth Drivers
Adoption of Ready-to-use Injectables to Drive Market Growth
Growing demand for convenient, safe, and efficient antiemetic delivery, along with a rising focus on pediatric and high-risk cancer patients, is shaping the evolution of the market. For instance, in July 2024, Amneal Pharmaceuticals and Steriscience launched a novel ready-to-use injectable formulation of fosaprepitant, free from Polysorbate 80 and requiring no reconstitution. This single-dose vial, FOCINVEZ, supports adult and pediatric CINV prevention in highly and moderately emetogenic chemotherapy. The innovation enhances hospital and clinic workflow efficiency while improving patient safety and adherence. This launch is expected to significantly contribute to market growth during the forecast period by offering differentiated, patient-centric antiemetic solutions that align with ongoing demand for ready-to-administer therapies.
Chemotherapy Induced Nausea Vomiting Market Trends
Major market trends include rising clinical innovations, preference for combination therapies, and an emphasis on providing solutions for children among others.
Clinical Innovations to Bring Advanced Solutions in the Market
In October 2024, a phase 3 clinical study presented at the ASCO Quality Care Symposium revealed that olanzapine significantly outperformed prochlorperazine in managing severe refractory nausea after chemotherapy. This highlights a shift toward patient-centric treatment strategies beyond standard antiemetics. As clinical validation supports olanzapine’s efficacy, its wider adoption is expected to reshape supportive oncology care and drive growth in the CINV market during the forecast period.
Strategic Licensing to Fuel Combination Therapies and Impact Market Size Positively
In January 2023, Glenmark Pharmaceuticals launched Akynzeo IV, an injectable fixed-dose combination of fosnetupitant and palonosetron, under an exclusive licensing deal with Helsinn. This ready-to-dilute formulation simplifies administration in clinical settings, especially for highly emetogenic chemotherapy. Strategic partnerships like this are strengthening access to next-generation combination therapies, accelerating product adoption, and boosting the market’s growth.
Rising Pediatric Focus to Advance Targeted Chemotherapy Induced Nausea Vomiting Treatment
The growing inclusion of pediatric patients in chemotherapy regimens is increasing demand for age-specific antiemetic treatments. Formulations approved for use in young children are gaining traction as healthcare providers prioritize early intervention. This demographic shift is prompting pharmaceutical companies to invest in research and regulatory approvals for pediatric-friendly CINV therapies, opening new avenues for market expansion in the coming years.
Increased Hospital Reliance on Ready-to-use Injectables Supporting Chemotherapy Induced Nausea Vomiting Market Growth
With healthcare systems seeking efficiency and safety in drug administration, the demand for ready-to-use injectables is rising. These formulations reduce preparation time, minimize contamination risks, and improve workflow in oncology settings. As more antiemetic drugs are developed in pre-filled or single-dose formats, hospitals and cancer centres are expected to prefer them over traditional injectable therapies, thereby supporting growth in the market.
Chemotherapy Induced Nausea Vomiting Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
- Acute Emesis
- Delayed Emesis
- Anticipatory Emesis
- Refractory Emesis
- Nk-1 receptor antagonist
- Serotonin receptor antagonist
- Others
- Children
- Adults
- Branded
- Generic
- Oral
- Parenteral
- Hospitals
- Specialty Clinics
- Homecare Settings
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- United States
- United Kingdom
- Germany
- France
- Italy
- Spain
- Japan
- India
Serotonin Receptor Antagonists to Lead the Market Share by Therapy
Serotonin receptor antagonists are expected to hold a substantial share due to their widespread use and proven efficacy. NK-1 receptor antagonists follow, offering enhanced control in combination therapies. The others category, including corticosteroids and novel agents, holds a smaller share but contributes to comprehensive treatment approaches, especially in patients with refractory symptoms or complex chemotherapy regimens.
Chemotherapy Induced Nausea Vomiting Market Analysis by Region
The United States is likely to hold the largest market share, driven by high chemotherapy adoption rates and access to advanced antiemetic therapies. Japan follows closely due to its ageing population and strong oncology care infrastructure. European countries Germany, France, Italy, Spain, and the UK, exhibit moderate growth with standardized treatment guidelines. India shows emerging potential, though limited access and affordability constraints currently restrict its overall market contribution.
Leading Players in the Chemotherapy Induced Nausea Vomiting Market
The key features of the market report comprise epidemiology, clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Dr. Reddy’s Laboratories Ltd.
Founded in 1984 and headquartered in Hyderabad, India, Dr. Reddy’s Laboratories is a global pharmaceutical company with a strong presence in generics, active pharmaceutical ingredients, and biosimilars. In the chemotherapy-induced nausea and vomiting (CINV) market, it offers antiemetic formulations like Ondansetron and Palonosetron, supporting cancer care through affordable, high-quality medicines distributed across regulated and emerging markets.
CTX Lifesciences
Established in 2004 and headquartered in Surat, India, CTX Lifesciences is known for manufacturing APIs and intermediates, particularly for oncology and antiemetic segments. In the CINV market, the company provides active pharmaceutical ingredients like Ondansetron and Granisetron to global formulation companies, supporting cost-effective antiemetic drug production across various international regulatory frameworks.
Pfizer Inc.
Headquartered in New York, USA, and founded in 1849, Pfizer is one of the world's largest biopharmaceutical companies. In the chemotherapy-induced nausea and vomiting (CINV) segment, Pfizer markets leading antiemetic products like Emend (Aprepitant), an NK1 receptor antagonist. Its innovative oncology support therapies are widely used in hospitals and oncology clinics globally.
Glenmark Pharmaceuticals Inc.
Founded in 1977 and headquartered in Mumbai, India, Glenmark Pharmaceuticals operates internationally with a strong generics and specialty drug portfolio. In the chemotherapy induced nausea vomiting market, it offers generic formulations such as Ondansetron and Palonosetron. Glenmark supports global cancer treatment protocols by delivering accessible and effective antiemetic drugs to healthcare systems across developed and developing regions.
Other key players in the market include Gmt Pharma, Mountainside Medical, Cipla Limited, GlaxoSmithKline plc, Merck and Co. Inc., and Novartis AG.
Key Questions Answered in the Chemotherapy Induced Nausea Vomiting Market
- What was the chemotherapy induced nausea vomiting market value in 2024?
- What is the chemotherapy induced nausea vomiting market forecast outlook for 2025-2034?
- What are the major factors aiding the chemotherapy induced nausea vomiting market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major chemotherapy induced nausea vomiting market trends?
- Which typewill lead the market segment?
- Which therapy will lead the market segment?
- Which population type will lead the market segment?
- Which drug type will lead the market segment?
- Which route of administration will lead the market segment?
- Which end user will lead the market segment?
- Which distribution channel will lead the market segment?
- Who are the key players involved in the chemotherapy induced nausea vomiting market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Chemotherapy Induced Nausea Vomiting Market Overview – 8 Major Markets
- 3.1 Chemotherapy Induced Nausea Vomiting Market Historical Value (2018-2024)
- 3.2 Chemotherapy Induced Nausea Vomiting Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Chemotherapy Induced Nausea Vomiting Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Chemotherapy Induced Nausea Vomiting Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence, by Country
- 7.2.1 United States
- 7.2.2 United Kingdom
- 7.2.3 Germany
- 7.2.4 France
- 7.2.5 Italy
- 7.2.6 Spain
- 7.2.7 India
- 7.2.8 Japan
- 7.3 Total Diagnosed Cases of Chemotherapy Induced Nausea Vomiting, By Country
- 7.4 Gender-specific Prevalence of Chemotherapy Induced Nausea Vomiting, By Country
- 7.5 Age-specific Prevalence of Chemotherapy Induced Nausea Vomiting, By Country
- 7.6 Treatment Seeking Rate of Chemotherapy Induced Nausea Vomiting, By Country
- 8 Chemotherapy Induced Nausea Vomiting Market Landscape – 8 Major Markets
- 8.1 Chemotherapy Induced Nausea Vomiting Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Chemotherapy Induced Nausea Vomiting Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Therapy
- 8.2.3 Analysis by Drug Type
- 8.2.4 Analysis by Route of Administration
- 9 Clinical Trials and Pipeline Analysis
- 9.1 Analysis by Trial Registration Year
- 9.2 Analysis by Trial Status
- 9.3 Analysis by Trial Phase
- 9.4 Analysis by Therapeutic Area
- 9.5 Analysis by Geography
- 9.6 Drug Pipeline Analysis
- 10 Chemotherapy Induced Nausea Vomiting Market Challenges and Unmet Needs
- 10.1 Treatment Pathway Challenges
- 10.2 Compliance and Drop-Out Analysis
- 10.3 Awareness and Prevention Gaps
- 11 Cost of Treatment
- 12 Chemotherapy Induced Nausea Vomiting Market Dynamics
- 12.1 Market Drivers and Constraints
- 12.2 SWOT Analysis
- 12.2.1 Strengths
- 12.2.2 Weaknesses
- 12.2.3 Opportunities
- 12.2.4 Threats
- 12.3 PESTEL Analysis
- 12.3.1 Political
- 12.3.2 Economic
- 12.3.3 Social
- 12.3.4 Technological
- 12.3.5 Legal
- 12.3.6 Environment
- 12.4 Porter’s Five Forces Model
- 12.4.1 Bargaining Power of Suppliers
- 12.4.2 Bargaining Power of Buyers
- 12.4.3 Threat of New Entrants
- 12.4.4 Threat of Substitutes
- 12.4.5 Degree of Rivalry
- 12.5 Key Demand Indicators
- 12.6 Key Price Indicators
- 12.7 Industry Events, Initiatives, and Trends
- 12.8 Value Chain Analysis
- 13 Chemotherapy Induced Nausea Vomiting Market Segmentation (218-2034) - 8 Major Markets
- 13.1 Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Type
- 13.1.1 Market Overview
- 13.1.2 Acute Emesis
- 13.1.3 Delayed Emesis
- 13.1.4 Anticipatory Emesis
- 13.1.5 Refractory Emesis
- 13.2 Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Therapy
- 13.2.1 Market Overview
- 13.2.2 Nk-1 receptor antagonist
- 13.2.3 Serotonin receptor antagonist
- 13.2.4 Others
- 13.3 Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Population Type
- 13.3.1 Market Overview
- 13.3.2 Children
- 13.3.3 Adults
- 13.4 Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Drug Type
- 13.4.1 Market Overview
- 13.4.2 Branded
- 13.4.3 Generic
- 13.5 Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Oral
- 13.5.3 Parenteral
- 13.6 Chemotherapy Induced Nausea Vomiting Market (2018-2034) by End User
- 13.6.1 Market Overview
- 13.6.2 Hospitals
- 13.6.3 Specialty Clinics
- 13.6.4 Homecare Settings
- 13.6.5 Others
- 13.7 Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Distribution Channel
- 13.7.1 Market Overview
- 13.7.2 Hospital Pharmacies
- 13.7.3 Retail Pharmacies
- 13.7.4 Online Pharmacies
- 13.8 Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Region
- 13.8.1 Market Overview
- 13.8.2 United States
- 13.8.3 United Kingdom
- 13.8.4 Germany
- 13.8.5 France
- 13.8.6 Italy
- 13.8.7 Spain
- 13.8.8 Japan
- 13.8.9 India
- 14 United States Chemotherapy Induced Nausea Vomiting Market (218-2034)
- 14.1 United States Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Type
- 14.1.1 Market Overview
- 14.1.2 Acute Emesis
- 14.1.3 Delayed Emesis
- 14.1.4 Anticipatory Emesis
- 14.1.5 Refractory Emesis
- 14.2 United States Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Therapy
- 14.2.1 Market Overview
- 14.2.2 Nk-1 receptor antagonist
- 14.2.3 Serotonin receptor antagonist
- 14.2.4 Others
- 14.3 United States Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Population Type
- 14.3.1 Market Overview
- 14.3.2 Children
- 14.3.3 Adults
- 14.4 United States Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Drug Type
- 14.4.1 Market Overview
- 14.4.2 Branded
- 14.4.3 Generic
- 14.5 United States Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Route of Administration
- 14.5.1 Market Overview
- 14.5.2 Oral
- 14.5.3 Parenteral
- 14.6 United States Chemotherapy Induced Nausea Vomiting Market (2018-2034) by End User
- 14.6.1 Market Overview
- 14.6.2 Hospitals
- 14.6.3 Specialty Clinics
- 14.6.4 Homecare Settings
- 14.6.5 Others
- 14.7 United States Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Distribution Channel
- 14.7.1 Market Overview
- 14.7.2 Hospital Pharmacies
- 14.7.3 Retail Pharmacies
- 14.7.4 Online Pharmacies
- 15 United Kingdom Chemotherapy Induced Nausea Vomiting Market (218-2034)
- 15.1 United Kingdom Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Type
- 15.2 United Kingdom Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Therapy
- 15.3 United Kingdom Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Population Type
- 15.4 United Kingdom Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Drug Type
- 15.5 United Kingdom Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Route of Administration
- 15.6 United Kingdom Chemotherapy Induced Nausea Vomiting Market (2018-2034) by End User
- 15.7 United Kingdom Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Distribution Channel
- 16 Germany Chemotherapy Induced Nausea Vomiting Market (218-2034)
- 16.1 Germany Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Type
- 16.2 Germany Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Therapy
- 16.3 Germany Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Population Type
- 16.4 Germany Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Drug Type
- 16.5 Germany Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Route of Administration
- 16.6 Germany Chemotherapy Induced Nausea Vomiting Market (2018-2034) by End User
- 16.7 Germany Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Distribution Channel
- 17 France Chemotherapy Induced Nausea Vomiting Market (218-2034)
- 17.1 France Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Type
- 17.2 France Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Therapy
- 17.3 France Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Population Type
- 17.4 France Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Drug Type
- 17.5 France Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Route of Administration
- 17.6 France Chemotherapy Induced Nausea Vomiting Market (2018-2034) by End User
- 17.7 France Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Distribution Channel
- 18 Italy Chemotherapy Induced Nausea Vomiting Market (218-2034)
- 18.1 Italy Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Type
- 18.2 Italy Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Therapy
- 18.3 Italy Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Population Type
- 18.4 Italy Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Drug Type
- 18.5 Italy Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Route of Administration
- 18.6 Italy Chemotherapy Induced Nausea Vomiting Market (2018-2034) by End User
- 18.7 Italy Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Distribution Channel
- 19 Spain Chemotherapy Induced Nausea Vomiting Market (218-2034)
- 19.1 Spain Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Type
- 19.2 Spain Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Therapy
- 19.3 Spain Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Population Type
- 19.4 Spain Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Drug Type
- 19.5 Spain Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Route of Administration
- 19.6 Spain Chemotherapy Induced Nausea Vomiting Market (2018-2034) by End User
- 19.7 Spain Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Distribution Channel
- 20 Japan Chemotherapy Induced Nausea Vomiting Market (218-2034)
- 20.1 Japan Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Type
- 20.2 Japan Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Therapy
- 20.3 Japan Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Population Type
- 20.4 Japan Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Drug Type
- 20.5 Japan Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Route of Administration
- 20.6 Japan Chemotherapy Induced Nausea Vomiting Market (2018-2034) by End User
- 20.7 Japan Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Distribution Channel
- 21 India Chemotherapy Induced Nausea Vomiting Market (218-2034)
- 21.1 India Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Type
- 21.2 India Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Therapy
- 21.3 India Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Population Type
- 21.4 India Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Drug Type
- 21.5 India Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Route of Administration
- 21.6 India Chemotherapy Induced Nausea Vomiting Market (2018-2034) by End User
- 21.7 India Chemotherapy Induced Nausea Vomiting Market (2018-2034) by Distribution Channel
- 22 Regulatory Framework
- 22.1 Regulatory Overview
- 22.2 US FDA
- 22.3 EU EMA
- 22.4 Japan PMDA
- 22.5 India CDSCO
- 22.6 Others
- 23 Patent Analysis
- 23.1 Analysis by Technology
- 23.2 Analysis by Publication Year
- 23.3 Analysis by Issuing Authority
- 23.4 Analysis by Patent Age
- 23.5 Analysis by CPC Analysis
- 23.6 Analysis by Patent Valuation
- 24 Grants Analysis
- 24.1 Analysis by Year
- 24.2 Analysis by Amount Awarded
- 24.3 Analysis by Issuing Authority
- 24.4 Analysis by Grant Application
- 24.5 Analysis by Funding Institute
- 24.6 Analysis by NIH Departments
- 24.7 Analysis by Recipient Organization
- 25 Funding and Investment Analysis
- 25.1 Analysis by Funding Instances
- 25.2 Analysis by Type of Funding
- 25.3 Analysis by Funding Amount
- 25.4 Analysis by Leading Players
- 25.5 Analysis by Leading Investors
- 25.6 Analysis by Geography
- 26 Strategic Initiatives
- 26.1 Analysis by Partnership Instances
- 26.2 Analysis by Type of Initiative
- 26.3 Analysis by Leading Players
- 26.4 Analysis by Geography
- 27 Supplier Landscape
- 27.1 Market Share Analysis, By Country (Top 5 Companies)
- 27.2 Dr. Reddy’s Laboratories Ltd.
- 27.2.1 Financial Analysis
- 27.2.2 Product Portfolio
- 27.2.3 Demographic Reach and Achievements
- 27.2.4 Company News and Developments
- 27.2.5 Certifications
- 27.3 CTX Lifesciences
- 27.3.1 Financial Analysis
- 27.3.2 Product Portfolio
- 27.3.3 Demographic Reach and Achievements
- 27.3.4 Company News and Developments
- 27.3.5 Certifications
- 27.4 Pfizer Inc.
- 27.4.1 Financial Analysis
- 27.4.2 Product Portfolio
- 27.4.3 Demographic Reach and Achievements
- 27.4.4 Company News and Developments
- 27.4.5 Certifications
- 27.5 Glenmark Pharmaceuticals Inc.
- 27.5.1 Financial Analysis
- 27.5.2 Product Portfolio
- 27.5.3 Demographic Reach and Achievements
- 27.5.4 Company News and Developments
- 27.5.5 Certifications
- 27.6 Gmt Pharma
- 27.6.1 Financial Analysis
- 27.6.2 Product Portfolio
- 27.6.3 Demographic Reach and Achievements
- 27.6.4 Company News and Developments
- 27.6.5 Certifications
- 27.7 Mountainside Medical
- 27.7.1 Financial Analysis
- 27.7.2 Product Portfolio
- 27.7.3 Demographic Reach and Achievements
- 27.7.4 Company News and Developments
- 27.7.5 Certifications
- 27.8 Cipla Limited
- 27.8.1 Financial Analysis
- 27.8.2 Product Portfolio
- 27.8.3 Demographic Reach and Achievements
- 27.8.4 Company News and Developments
- 27.8.5 Certifications
- 27.9 GlaxoSmithKline plc
- 27.9.1 Financial Analysis
- 27.9.2 Product Portfolio
- 27.9.3 Demographic Reach and Achievements
- 27.9.4 Company News and Developments
- 27.9.5 Certifications
- 27.10 Merck and Co. Inc.
- 27.10.1 Financial Analysis
- 27.10.2 Product Portfolio
- 27.10.3 Demographic Reach and Achievements
- 27.10.4 Company News and Developments
- 27.10.5 Certifications
- 27.11 Novartis AG
- 27.11.1 Financial Analysis
- 27.11.2 Product Portfolio
- 27.11.3 Demographic Reach and Achievements
- 27.11.4 Company News and Developments
- 27.11.5 Certifications
- 28 Chemotherapy Induced Nausea Vomiting Market - Distribution Model (Additional Insight)
- 28.1 Overview
- 28.2 Potential Distributors
- 28.3 Key Parameters for Distribution Partner Assessment
- 29 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 30 Payment Methods (Additional Insight)
- 30.1 Government Funded
- 30.2 Private Insurance
- 30.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
